Ruth Duncan

Updated August 2017

Recent Reviews



Duncan R and Gaspar R (2011) Nanomedicine(s) under the microscope, Molecular Pharmaceutics 8, 2101- 2141.


Ehmann F, Sakai-Kato K, Duncan R, Hernan D, Pita R, Vidal J-M, Kohli A, Tothfalusi L, Sanh A, Tinton S, Robert J-L, Silva Lima B, Papaluca Amati M (2013) Next generation nanomedicines and nanosimilars: EU Regulators initiative relating to the development and evaluation of nanomedicines, Nanomedicine 8(5) 849-856.


Duncan R (2014) Nanomedicine(s) and their Regulation: An Overview. In : Handbook of Safety Assessment of Nanomaterials: From Toxicological Testing to Personalised Medicine ,Ed. B Fadeel, Pan Stanford Publishing, Ltd., Singapore, pp 1-41.


Duncan R (2006) Polymer conjugates as anticancer nanomedicines. Nature Reviews Cancer 6 688-701
Duncan R (2003) The dawning era of polymer therapeutics. Nature Reviews Drug Discovery 2 (5) 347-360.
Duncan R and Izzo L (2005) Dendrimer biocompatibility and toxicity. Adv. Drug Del. Rev. 57,2215-2237.
Duncan R (1992) Drug-Polymer Conjugates: potential for improved chemotherapy.Anti-Cancer Drugs 3, 175-210
Duncan R, Dimitrijevic S and Evagorou E. (1996) The role of polymer conjugates in te diagnosis and treatment of cancer. S.T.P. Pharma 6,237-263.

You are viewing the text version of this site.

To view the full version please install the Adobe Flash Player and ensure your web browser has JavaScript enabled.

Need help? check the requirements page.

Get Flash Player